Gilead Sciences, Inc. (GILD) Close To Dominating Second Multibillion Market With Solvadi
2/21/2014 8:29:28 AM
It's rare enough for a biotech to succeed, and even rarer for a biotech to ultimately dominate a therapeutic area. But to do it twice? That's almost unheard of, and yet here we are with Gilead Sciences (NASDAQ: GILD ) . Building off of a $9 billion franchise in HIV, Gilead is set to become the leader in the emerging multibillion-dollar hepatitis C (HCV) market.
Help employers find you! Check out all the jobs and post your resume.
comments powered by